NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**CONFIDENTIAL**

## Demo Report

**Report Issued** 12/02/2022 06:00
**Last Report Issued** 06/27/2022 14:35

**88888**
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

**Patient Name** 2532B-POS
**Patient ID** 2532B-POS
**Chain** 22001670
**DOB** Not Given
**Sex** Not Given
**Workorder** 22001670

**Received** 06/24/2022

---

**Lab ID** 22001670-001
**Matrix** Blood
**Patient Name** 2532B-POS
**Patient ID** 2532B-POS
**Container Type** Lavender (Purple) Cap Glass Tube

**Collect Dt/Tm** Not Given
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Results were removed from report on 06/27/2022.

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|---|---|---|---|---|
| **2532B Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Blood** | | | | |
| Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) | | | | |
| Teriflunomide (Pre-Pregnancy) | 20 | ng/mL | 5.0 | ELEVATED |
| Synonym(s): Leflunomide Metabolite | | | | |
| Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is a metabolite of leflunomide. | | | | |
| Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. | | | | |
| The blood to plasma ratio is 0.5 to 0.7. | | | | |
| The drug carries a black box warning for hepatotoxicity and pregnancy. | | | | |

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.